CBD Life Sciences Inc (PK) (CBDL) 뉴스

That would be considered fraud or stock manipulation please be quite they won't get another r/s approved revenue is up first quarter will be big army deal any minute 

They are going to sell billions. What do you think are filling buys every day? Dilution. Keep ignoring this is not the first time. Same as before last r/s. There is no share buyback. They are selling new shares.

Company crooked folks toooo many shares ceo is so full of chit

You keep saying they increased the a/s when they didn't so everything else you say is irrelevant 

With what money? Buyback lol. They increased the a/s. All day every day dilution fills buys by fools.

Even with a 500% increase. Notice they never post numbers just a %. That is because revenues still tiny under 1 million. Vs the billions of dilution shares before and after r/s for the last 5 years. Volume is slowing. They will take it to .0001 again soon enough. All they care about is selling shares. 5 years of this and some still blind to it.

Ceo is about lie, steal, wash , rinse and repeat . Cbdl has no value

Ceo a flat out crook buyer beware. This ceo doesn’t give two chits about shareholders.

CBD Life Sciences Inc. (CBDL) Company Online Sales Up 500%Press Release | 04/10/2025

With the global wellness industry exploding past $7 trillion, CBDL positions itself at the intersection of CBD, mushrooms, and modern healing - delivering real results and red-hot returns.

SCOTTSDALE, AZ / ACCESS Newswire / April 10, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL) is thrilled to announce a 500% increase in online sales this past quarter, catapulting the company into a new phase of growth as it rides the tidal wave of a rapidly expanding global wellness economy.

This milestone reflects the company's relentless focus on innovation, clean ingredients, and product efficacy. From cutting-edge CBD topicals to adaptogenic mushroom blends, CBDL is gaining significant traction in both consumer markets and investor circles.

"We're not just selling CBD anymore," said CEO Lisa Nelson. "We're creating a new category of functional wellness - one that blends the healing powers of CBD, mushrooms, and natural ingredients backed by science and built for today's lifestyles."

Positioned in the Heart of a $7 Trillion Wellness Boom
The wellness industry is booming - valued at $7.1 trillion globally, with natural health solutions like CBD and functional mushrooms taking center stage. CBDL is uniquely positioned at this intersection, offering products that tap into two of the most explosive markets in the world:

The CBD market, projected to exceed $60 billion by 2030

The functional mushroom market, expected to surpass $24 billion by 2032

CBD Life Sciences Inc. is going beyond traditional CBD by launching wellness-forward formulations that include Reishi, Lion's Mane, and Ashwagandha - powerful adaptogens known for reducing stress, improving focus, boosting immunity, and fighting inflammation. The company's line of CBD Kava & Kratom Shots is also gaining momentum as a natural alternative to caffeine, energy drinks, and synthetic stress relief.

CBDL's Momentum is Just Getting Started:

500%+ online sales growth in Q1 2025

Top-sellers: 3000MG Pain Relief Cream, CBD Kava & Kratom Shots, Mushroom Wellness Blends

Retail Expansion:

Now selling on Walmart Marketplace

Products available through DoorDash in select markets

More e-commerce and delivery partnerships in development

Innovative Product Development:

Proprietary Nano-CBD Technology for maximum bioavailability

Launch of adaptogenic mushroom products including Reishi, Lion's Mane, and Ashwagandha

Domestic Production & Compliance:

All products made in the USA

Third-party tested for quality and consistency

Clean-label ingredients, no artificial fillers

For Investors
CBD Life Sciences Inc. is not just scaling - it's setting the pace. By strategically expanding into multiple billion-dollar wellness verticals, CBDL is leveraging its momentum to build a brand that is future-proof, health-focused, and ready for mass market adoption.

With more consumers turning to plant-based, functional wellness solutions every day, CBDL stands at the forefront of a generational shift in how people approach health and healing.

For investors seeking to get in on the ground floor of the next wave in natural wellness, CBD Life Sciences Inc. is the name to watch.

About CBD Life Sciences Inc.
CBD Life Sciences Inc. (CBDL) is a leading innovator in the wellness and alternative health sector, specializing in high-quality CBD and functional mushroom products designed to enhance well-being. With a commitment to scientific research and consumer safety, CBDL continues to push the boundaries of holistic health solutions, creating opportunities for exponential growth in a rapidly evolving market.

Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com

Stay Connected & Be the First to Try Our New Functional Mushroom Products!

Mushroom Madness Instagram: https://www.instagram.com/mushroom.madnessaz

Mushroom Madness Website: https://www.mushroommadness.shop

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720

SOURCE: CBD Life Sciences, Inc.


View the original press release on ACCESS Newswire
https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Company-Online-Sales-Up-500?id=473233

Buy back shares will be started.

$CBDL CBD Life Sciences Inc. (CBDL) Company Online Sales Up 500%

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cbd-life-sciences-inc-cbdl-company-online-sales-up-500-1013080

With the global wellness industry exploding past $7 trillion, CBDL positions itself at the intersection of CBD, mushrooms, and modern healing - delivering real results and red-hot returns.

SCOTTSDALE, AZ / ACCESS Newswire / April 10, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL) is thrilled to announce a 500% increase in online sales this past quarter, catapulting the company into a new phase of growth as it rides the tidal wave of a rapidly expanding global wellness economy.

This milestone reflects the company's relentless focus on innovation, clean ingredients, and product efficacy. From cutting-edge CBD topicals to adaptogenic mushroom blends, CBDL is gaining significant traction in both consumer markets and investor circles.

"We're not just selling CBD anymore," said CEO Lisa Nelson. "We're creating a new category of functional wellness - one that blends the healing powers of CBD, mushrooms, and natural ingredients backed by science and built for today's lifestyles."

Positioned in the Heart of a $7 Trillion Wellness Boom
The wellness industry is booming - valued at $7.1 trillion globally, with natural health solutions like CBD and functional mushrooms taking center stage. CBDL is uniquely positioned at this intersection, offering products that tap into two of the most explosive markets in the world:

The CBD market, projected to exceed $60 billion by 2030

The functional mushroom market, expected to surpass $24 billion by 2032

CBD Life Sciences Inc. is going beyond traditional CBD by launching wellness-forward formulations that include Reishi, Lion's Mane, and Ashwagandha - powerful adaptogens known for reducing stress, improving focus, boosting immunity, and fighting inflammation. The company's line of CBD Kava & Kratom Shots is also gaining momentum as a natural alternative to caffeine, energy drinks, and synthetic stress relief.

CBDL's Momentum is Just Getting Started:

500%+ online sales growth in Q1 2025

Top-sellers: 3000MG Pain Relief Cream, CBD Kava & Kratom Shots, Mushroom Wellness Blends

Retail Expansion:

Now selling on Walmart Marketplace

Products available through DoorDash in select markets

More e-commerce and delivery partnerships in development

Innovative Product Development:

Proprietary Nano-CBD Technology for maximum bioavailability

Launch of adaptogenic mushroom products including Reishi, Lion's Mane, and Ashwagandha

Domestic Production & Compliance:

All products made in the USA

Third-party tested for quality and consistency

Clean-label ingredients, no artificial fillers

For Investors
CBD Life Sciences Inc. is not just scaling - it's setting the pace. By strategically expanding into multiple billion-dollar wellness verticals, CBDL is leveraging its momentum to build a brand that is future-proof, health-focused, and ready for mass market adoption.

With more consumers turning to plant-based, functional wellness solutions every day, CBDL stands at the forefront of a generational shift in how people approach health and healing.

For investors seeking to get in on the ground floor of the next wave in natural wellness, CBD Life Sciences Inc. is the name to watch.

I said before the last r/s. That even .0001 was to much to pay. Anyone who did before this r/s lost their money. To ignore the dilution scam this is. Means anyone buying will lose.

$0.0001s are cheaper than $0.0003s. The reverse/split was a bad idea, as they usually are (especially for OTC stocks).

The A/S is then 6.5 billion. You will end up like all the ones before this r/s. Who all argued the same as you are. This is a dilution scam. They get rich selling shares not CBD.

Nice recent buys to sells been green last few days 

I'm not wrong no they didn't raise a/s so please shut the fuvk up you're not saving anybody you're just an annoying dweeb 

Wrong yes they did. How do you think buys are being filled at these levels? It is called dilution. The A/s is 6.5 billion. Maybe not 8.5. The dilution here never stops. Keep buying. You will lose it all. Ignore the dilution record here for 5 years is not very smart.

Army deal and yearly coming up followed by first quarter in may well be back to 001

They didn't increase the a/s your information is wrong and judging by the ease of getting the right information I believe your opinions are wrong too 

Just like before this r/s. Ticking down now ask is .0003.Some just ignore the history here but it does not change.

Under valued lol. They have diluted billions and still are. For all the dilution and r/s what did they produce? Over 5 years little as revenues are tiny. Only shares filling buys are shares sold by the company. Never ending dilution. When back and stuck at .0001 again. You will lose any money buying this stock. Just ask shareholders in before last r/s. Gone. Also they put out a lying pr saying share buyback. The increase a/s and kept on diluting. Crooks.

THis undervalued stock will take off soon with more good news coming.

Don't worry 3 is a good buy. This company has good future. Revenue will come fast, PPS is undervalued, CEO plan to buy back shares.. Now they need cash for coming merge. Dilution will stop very soon.

Everyday when they are diluting and have billions to sell. People buying this will lose it all. Same as others before the last r/s. Some people are just blind to this dilution scam. Only ones selling at these levels are the company dilution shares.

Big dump eod 

He's full of shit, OTCMARKETS CLEARLY SHOWS 6.5B.

It was news link I saw here a few weeks ago. Say you are right it is 6.5 billion. That is still billions they will dilute and lied about a share buyback. The dilution has not ended here for over 5 years. If we go back to before r/s. It is trillions on a presplit basis. Just like before the last r/s. Share holders will be diluted down to .00001 again. Not matter will it happen just when. They sell little for revenues vs all the dilition for years.

Where are you seeing 8.5 billion otc markets was just updated as of 04/02/2025 at 6.5 million where are you seeing 8 

As I said and have been right for years. Dilution is again heading it to .0001. To sell billions of shares .00001 is inevitable.

Wrong a/s is now 8.5 billion. So much for the share buyback pr lie. Wake up this is and has been a dilution scam for 5 years. The sales are so tiny vs the massive dilution.

8.5 billion a/s says nothing will stop this dilution. They lied about a share buyback. They are not getting any military contract. They are a tiny company that does not sell much CBD. They lie!

The the company increased a/s to 8.5 billion. After they said they do a share buyback lie. This is doing the same as before previous r/s. When stuck again at .00001. Getting closer as they add shares to the o/s. Then will they be able to have another r/s approved is only question.

These pop up shops are not gonna do it. We need need those armed forces contracts!!

Just a few weeks ago it was trading 100+ m a day most was 400+m weekly it could but would take killer news 

Historically has this stock ever traded 200,000,000 shares in one day?

That can get traded in a day with the right news 

They didn't increase A/S after R/S, that's bullshit! Still sitting at 6.5B.

200,000,000 shares diluted over past month, that's 60k! That's a good one months pay.

200,000,000 shares diluted March 2nd - April 2nd

LOL. The buys are filled by new share dilution. That is why stuck even when days of over 100 million. The dilution will never end. They have 8.5 billion A/S to sell fools. Nothing ever changes here. Massive dilution and small revenues.

Nice buys 

Yeah sales seem like more dilution I doubt that's all retail buy back was a lie but still they want to have some value to their stock if they're gonna sell shares everyone wants to sell at higher price even them 

The volume was big the last 3 days. No run up. Why? Massive dilution fillings buys is why. That never changes. Only share filling buys are dilution. All they care about is selling billions of shares.

Few nice buys later on in the day here could be good sign where is this army news 

We will see but I agree. They likely would not get another r/s approved. They increased the A/S after lying about a share buyback. This is going the same as after prior r/s. Once down to .00001. Done as I doubt can do another r/s.

They said no more r/s and I'm not sure how many more the sec would allow .. army news soon 

Wrong. They just increased a/s to 8.5 billion. This is never ending massive dilution. Just like before last r/s and now after. Before the r/s it had one spike. Just like we saw a short one after current r/s. Then like before. Big increase in A/s. Lies about share buyback then the increase. When this is stuck at .000001 like before this r/s. Buying the shares was a loser. Just ask anyone in before last r/s. The volume since that A/S increase. Insane. How do they get so many fools to buy in. SAD.

Shake out before the rip back to 001 soon 

Buy back in at 0.0003 today. See 0.0006 in few days

CBD Life Sciences Inc. (CBDL) Powers Forward with Disruptive Brain-Boosting Mushroom ApplicationsPress Release | 04/01/2025

The global functional mushroom market is projected to reach $19.3 billion by 2030, driven by cutting-edge research revealing their potential to enhance memory, nerve growth, and overall cognitive health.

SCOTTSDALE, AZ / ACCESS Newswire / April 1, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL) is making bold strides into the booming functional mushroom sector, positioning itself at the forefront of a revolution that is reshaping cognitive health and wellness. As the demand for natural, scientifically backed solutions grows, CBDL's strategic expansion into brain-boosting mushroom applications signals a major step forward in harnessing the power of nature to optimize mental performance, longevity, and overall well-being.

Unlocking the Power of Brain-Boosting Mushrooms

Scientific studies have revealed that certain mushrooms, particularly Lion's Mane (Hericium erinaceus), contain bioactive compounds that support nerve regeneration and improve cognitive function. Researchers at the University of Queensland recently identified specific compounds that promote nerve growth and enhance memory, validating what ancient medicine has long recognized. Additionally, emerging studies suggest that regular mushroom consumption may reduce the risk of neurodegenerative diseases such as Alzheimer's and Parkinson's.

By incorporating these groundbreaking discoveries into its product development pipeline, CBDL is setting the stage for an entirely new category of wellness products designed to support brain function, enhance learning ability, and provide neuroprotection against age-related decline. This move is more than just an expansion-it's an investment in the future of cognitive health, offering consumers an alternative to synthetic drugs with potentially harmful side effects.

A Multi-Billion Dollar Market with Limitless Potential

The global market for functional mushrooms is expanding at an exponential rate, with a projected value of $19.3 billion by 2030. Investors are taking notice as mushroom-based products gain mainstream traction, with companies developing innovative applications in health, sustainability, and even technology. The surge in consumer interest, coupled with increased scientific validation, has created a perfect storm for industry disruption, and CBDL is capitalizing on this momentum.

CBDL's strategic focus on this sector presents an enormous revenue-generating opportunity, aligning with the company's mission to pioneer the next frontier of holistic wellness. The market potential extends far beyond supplements-mushrooms are now being used in sustainable product development, biodegradable materials, and even robotics. Researchers have successfully harnessed electrical signals from mycelium to engineer fungi-controlled robotics, further proving that the future of innovation is deeply intertwined with mushrooms.

Addressing Public Health & Safety Concerns

With the rising popularity of mushroom-based wellness products, CBDL remains committed to safety and regulatory compliance. While some psychedelic mushroom edibles have raised concerns due to lack of regulation, CBDL ensures that its products are developed with strict quality control measures, harnessing only scientifically backed, non-psychedelic mushroom compounds for cognitive enhancement and neurological support.

Furthermore, as the FDA investigates safety concerns surrounding unregulated psychoactive mushroom products, CBDL is dedicated to setting the industry standard for transparency, efficacy, and consumer trust. This commitment reassures both consumers and investors that CBDL is not only a leader in innovation but also in safety and responsibility.

Why Shareholders Should Pay Attention

CBDL's expansion into the brain-boosting mushroom market represents a forward-thinking move that aligns with skyrocketing demand and industry-wide advancements. This initiative is not just about capitalizing on a growing trend-it's about positioning CBDL as a dominant force in a rapidly evolving sector with unlimited scalability. The ability to integrate mushrooms into multiple verticals, from health and wellness to sustainability and technology, makes this a game-changing pivot that opens the door to exponential growth and diversified revenue streams.

By investing in cutting-edge research, sustainable development, and high-quality formulations, CBDL is poised to capitalize on this revolutionary movement-bringing unparalleled value to both consumers and shareholders alike. The company's forward momentum reflects a vision beyond CBD and cannabis, solidifying its role as an innovator in the broader alternative wellness space.

As the world moves towards natural, effective, and sustainable health solutions, CBDL is not just following the trend-it is shaping the future. This latest venture into functional mushrooms cements the company's commitment to long-term growth, scientific excellence, and industry leadership.

Sky News Mushroom Video: https://www.youtube.com/watch?v=DA183RBkXSQ

About CBD Life Sciences Inc.

CBD Life Sciences Inc. (CBDL) is a leading innovator in the wellness and alternative health sector, specializing in high-quality CBD and functional mushroom products designed to enhance well-being. With a commitment to scientific research and consumer safety, CBDL continues to push the boundaries of holistic health solutions, creating opportunities for exponential growth in a rapidly evolving market.

Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com

Stay Connected & Be the First to Try Our New Functional Mushroom Products!

Mushroom Madness Instagram: https://www.instagram.com/mushroom.madnessaz

Mushroom Madness Website: https://www.mushroommadness.shop

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720

SOURCE: CBD Life Sciences, Inc.


View the original press release on ACCESS Newswire
https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Powers-Forward-with-Disruptive-Brain-Boosting-Mushroom-Applications?id=472242


CBD Life Sciences Inc. (CBDL) Announces Its Official Launch on Groupon.comPress Release | 02/04/2025

Groupon, with over 22.5 million active users and generating more than $550 million in annual revenue, now features CBDL's top-tier wellness products, unlocking massive e-commerce potential and positioning the company for explosive growth in the booming CBD industry.

SCOTTSDALE, AZ / ACCESS Newswire / February 4, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL), a trailblazer in the CBD and wellness market, is thrilled to announce its official launch on Groupon.com, one of the world's largest e-commerce deal platforms. This strategic expansion marks a major milestone in CBDL's aggressive growth strategy, placing its premium CBD products in front of millions of new potential customers while solidifying its position in the rapidly expanding $47 billion CBD industry.

By tapping into Groupon's powerhouse of 22.5 million active deal-seekers, CBDL gains access to a high-intent consumer base actively looking for health, wellness, and lifestyle products. With Groupon generating over $550 million in annual revenue and averaging more than 40 million transactions per year, this move significantly amplifies CBDL's direct-to-consumer reach and revenue potential.

A Power Move for Growth & Market Expansion

CBDL's official debut on Groupon is a game-changer. By leveraging Groupon's built-in marketing, deal-driven shopping experience, and trusted customer base, CBDL expects to see rapid traction, increased brand awareness, and accelerated sales growth.

"This is a major leap forward for CBD Life Sciences Inc.," said Lisa Nelson, President & CEO of CBDL. "We are laser-focused on expansion, and being featured on Groupon is a testament to our commitment to making high-quality CBD products more accessible than ever. With Groupon's massive audience and purchasing power, we are unlocking new revenue streams, increasing our market penetration, and taking our e-commerce strategy to the next level."

CBDL's first offering on Groupon, listed as The CBD Vault, features a selection of the company's best-selling CBD products designed for pain relief, relaxation, and overall wellness. This initial launch is just the beginning, as CBDL plans to continuously expand its product lineup to meet growing demand and solidify its presence in the digital retail space.

Why This Matters for Investors

This latest expansion aligns perfectly with CBDL's long-term growth strategy and positions the company to capitalize on the surging demand for premium CBD products in the U.S. and beyond.

E-commerce Dominance: Groupon's extensive reach provides CBDL with a direct gateway to millions of engaged shoppers, increasing brand exposure and revenue potential.

Scalability & Revenue Acceleration: With Groupon's marketing engine driving traffic, CBDL anticipates a strong increase in direct-to-consumer sales, boosting top-line revenue.

Industry Growth: The global CBD market is projected to exceed $47 billion by 2028, with the U.S. CBD market alone expected to reach $16 billion by 2026-CBDL is strategically positioning itself to capture significant market share.

Increased Shareholder Value: Every expansion move contributes to CBDL's aggressive trajectory toward sustained profitability, driving long-term shareholder value and bolstering investor confidence.

As CBDL continues its upward momentum with strategic partnerships, new product launches, and expansion into high-traffic retail platforms, this is just the beginning of what promises to be a breakthrough year for the company.

ð??? Shop CBDL on Groupon Now: The CBD Vault on Groupon

About CBD Life Sciences Inc. (CBDL)

CBD Life Sciences Inc. (OTC: CBDL) is a leading innovator in the CBD and wellness sector, committed to delivering premium, science-backed CBD products designed to enhance health, performance, and overall well-being. With an ever-expanding product portfolio and aggressive market expansion strategy, CBDL is shaping the future of CBD retail, both online and in major marketplaces nationwide.

For more information about CBD Life Sciences, Inc. and its product offerings, visit www.thecbdvault.com

Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720

SOURCE: CBD Life Sciences, Inc.

Related Images

https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Announces-Its-Official-Launch-on-Grouponcom?id=466598
View the original press release on ACCESS Newswire


CBD Life Sciences Inc. (CBDL) in Final Stages to Sell CBD Products on DoorDash PlatformPress Release | 01/14/2025

With DoorDash projecting over $10 billion in 2025 revenue, CBD Life Sciences Inc. is set to tap into one of the fastest-growing delivery markets in the country, potentially unlocking a multi-million dollar revenue stream and driving a projected 30-40% increase in annual revenue for CBDL.

SCOTTSDALE, ARIZONA / ACCESSWIRE / January 14, 2025 / CBD Life Sciences Inc. (OTC Pink:CBDL), a leading innovator in the CBD industry, proudly announces that it is in the final stages of securing approval to sell its premium CBD products on DoorDash, one of the most prominent on-demand delivery platforms in the United States. This development represents a significant step forward in CBDL's ongoing strategy to broaden its market reach and deliver high-quality CBD offerings to customers with greater convenience.

DoorDash's projected multi-billion-dollar revenue for 2025 underscores the massive growth potential in on-demand services. With a footprint spanning millions of households across the nation, DoorDash provides a unique and scalable avenue for CBDL to reach an even broader audience, enhancing product accessibility and driving exponential revenue growth. The CBD industry continues to surge, and this opportunity positions CBDL as a key player in transforming how consumers access wellness products.

"Being able to sell on DoorDash opens up an entirely new market for us," said Lisa Nelson, President and CEO of CBD Life Sciences Inc. "We are excited about the prospect of making our premium CBD products available through one of the most trusted delivery platforms in the U.S. This move not only aligns with our commitment to innovation but also positions us for substantial revenue growth in 2025 and beyond."

Once approved, CBDL plans to offer a wide range of its bestselling products, including high-potency 3000MG Pain Relief Cream and CBD Gummies, with same-day delivery in select markets. The company's CBD Gummies, known for their consistency and great taste, have been a hit with customers seeking convenient, delicious ways to incorporate wellness into their daily lives. This initiative enhances CBDL's competitive edge by catering to consumer demand for fast, convenient access to wellness products.

Expanding Market Potential and Growing Investor Confidence

In addition to expanding distribution channels, this opportunity also reinforces CBDL's aggressive growth strategy aimed at increasing shareholder value. Recent industry reports indicate that the U.S. CBD market is poised to grow at a compound annual growth rate (CAGR) of 28% over the next five years, driven by increased consumer awareness and demand for natural wellness solutions. With DoorDash's extensive logistics network and CBDL's premium product line, this expansion is expected to drive significant market penetration.

CBDL's focus on innovation doesn't stop at delivery partnerships. The company is also ramping up research and development efforts to introduce new products that cater to evolving consumer needs. These efforts reflect CBDL's dedication to staying ahead of market trends and ensuring sustained growth.

"This DoorDash opportunity is a game-changer," Nelson added. "It positions us at the forefront of a rapidly evolving market and gives us a significant advantage in capturing more market share while providing a seamless buying experience for our customers. We anticipate strong revenue growth and improved brand recognition as a direct result of this initiative."

CBDL continues to explore additional partnerships and opportunities to expand its reach in both the U.S. and international markets. With a strong product portfolio, a robust distribution strategy, and a relentless focus on growth, the company remains dedicated to delivering long-term value to its investors. Additionally, the company is committed to ongoing product innovation to meet the evolving needs of health-conscious consumers.

About CBD Life Sciences Inc.

CBD Life Sciences Inc. (OTC: CBDL) is a vertically integrated company focused on the development and commercialization of high-quality, innovative CBD-based products. With a diverse product line ranging from pain relief creams to gummies, CBDL is committed to enhancing the well-being of its customers through science-backed solutions. The company's mission is to lead the CBD industry by delivering exceptional products that promote better living.

For more information about CBD Life Sciences, Inc. and its product offerings, visit www.thecbdvault.com

Doordash Website: https://www.doordash.com/

Follow our social media for the latest updates!

X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720

SOURCE: CBD Life Sciences Inc.


View the original press release on accesswire.com
https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-in-Final-Stages-to-Sell-CBD-Products-on-DoorDash-Platform?id=464444


CBD Life Sciences, Inc. (CBDL) Secures Breakthrough Walmart Marketplace Approval for Mushroom Supplement, Setting the Stage for Unprecedented GrowthPress Release | 01/07/2025

Walmart Marketplace saw a 60% year-over-year growth in gross merchandise volume, with third-party sellers accounting for over 50% of online sales, contributing to Walmart's e-commerce revenue surpassing $100 billion in 2024. This makes it a powerful platform for rapid brand growth and a game-changing opportunity for CBDL's breakthrough product line.

SCOTTSDALE, AZ / ACCESSWIRE / January 7, 2025 / CBD Life Sciences, Inc. (OTC PINK:CBDL), a leader in wellness innovation, is thrilled to announce that its Mushroom Madness Rise Gummies, featuring a powerful Lion's Mane mushroom blend, have officially been approved for sale and are now available on Walmart Marketplace. This monumental approval opens the door for CBDL to tap into Walmart's expansive e-commerce ecosystem, providing a pathway to substantial revenue growth while strengthening its position in the rapidly expanding functional mushroom market.

Expanding Market Potential

The global functional mushroom market continues to surge, projected to reach $42.4 billion by 2028, with Lion's Mane products leading the charge due to their cognitive health benefits. CBDL's Mushroom Madness Rise Gummies, formulated for focus, clarity, and enhanced mental performance, are well-positioned to meet the increasing demand for natural wellness solutions.

Lisa Nelson, President and CEO of CBDL, commented on this milestone:
"This approval is more than just an entry into Walmart-it's a strategic step toward scaling our operations and driving significant shareholder value. We're not only gaining access to millions of health-conscious consumers but also leveraging Walmart's trusted platform to amplify our brand's reach and credibility."

The Walmart Marketplace Advantage

Walmart Marketplace, recognized as one of the fastest-growing online retail platforms, boasts over 100 million monthly visitors. With third-party sellers generating substantial portions of Walmart's e-commerce revenue, the platform offers unmatched scalability and visibility for emerging brands. CBDL's entry onto Walmart Marketplace provides logistical efficiencies, enhanced consumer trust, and a direct line to an enormous, ever-expanding customer base.

Industry reports indicate that third-party sellers often experience double-digit sales growth within months of launching on Walmart Marketplace. This offers CBDL an unprecedented opportunity to scale its revenues rapidly, further bolstered by Walmart's robust digital marketing support and fulfillment network.

Revenue Impact and Growth Strategy

CBD Life Sciences has already achieved impressive financial growth, recording a 1405.46% increase in revenue since February 2024. The company expects Walmart Marketplace to significantly enhance its revenue stream, given the rapid consumer adoption of functional mushroom products and CBD-infused supplements.

The Mushroom Madness Rise Gummies are a strategic addition to CBDL's product lineup, aligning with the company's commitment to offering scientifically formulated, high-efficacy wellness products. These gummies not only serve a growing wellness market but also position CBDL to capture a significant share of the $20 billion U.S. supplement industry.

As part of its long-term strategy, CBDL plans to launch additional top-selling products on Walmart Marketplace, including its highly anticipated nano-CBD supplements and mushroom-enhanced nutritional powders.

Commitment to Shareholders

CBDL remains steadfast in its mission to drive long-term shareholder value by continuously expanding into high-growth markets. The Walmart Marketplace approval is expected to further strengthen investor confidence, positioning the company as a market leader in innovative health solutions. With an expanding portfolio of products and a growing number of retail partnerships, CBDL is on track to deliver sustained financial growth and operational excellence.

Customers can purchase the product directly by visiting this link: https://www.walmart.com/ip/Rise-Mushrooms-Lion-s-Mane-Blend/14843512001?classType=REGULAR&from=/search

About CBD Life Sciences, Inc.
CBD Life Sciences, Inc. (OTC:CBDL) is a pioneering health and wellness company specializing in high-quality CBD products and functional supplements. With a focus on innovation, the company leverages advanced technology and scientific research to develop effective solutions that promote overall well-being. CBDL's diverse product range includes nano-enhanced CBD creamers, pain relief creams, and functional mushroom blends.

For more information about CBD Life Sciences, Inc. and its product offerings, visit www.thecbdvault.com

Follow our social media for the latest updates!

X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720

SOURCE: CBD Life Sciences Inc.

Related Images


View the original press release on accesswire.com
https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Secures-Breakthrough-Walmart-Marketplace-Approval-for-Mushroom-Supplement-Setting-the-Stage-f?id=463827